Investigational Drug Information for Darinaparsin
✉ Email this page to a colleague
What is the drug development status for Darinaparsin?
Darinaparsin is an investigational drug.
There have been 12 clinical trials for Darinaparsin.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 25th 2016.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, Peripheral, and Lymphoma, T-Cell. The leading clinical trial sponsors are Ziopharm, Solasia Pharma K.K., and Synex Consulting Korea Ltd.
There are thirty-four US patents protecting this investigational drug and four hundred and thirty-one international patents.
Summary for Darinaparsin
| US Patents | 34 |
| International Patents | 431 |
| US Patent Applications | 99 |
| WIPO Patent Applications | 73 |
| Japanese Patent Applications | 41 |
| Clinical Trial Progress | Phase 2 (2016-03-25) |
| Vendors | 26 |
Recent Clinical Trials for Darinaparsin
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Solasia Pharma K.K. | Phase 2 |
| A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea | Synex Consulting Korea Ltd. | Phase 1 |
| A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea | Solasia Pharma K.K. | Phase 1 |
Clinical Trial Summary for Darinaparsin
Top disease conditions for Darinaparsin
Top clinical trial sponsors for Darinaparsin
US Patents for Darinaparsin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Darinaparsin | ⤷ Sign Up | Anti-CS1 antibodies and antibody drug conjugates | AbbVie Biotherapeutics Inc. (Redwood City, CA) | ⤷ Sign Up |
| Darinaparsin | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Darinaparsin | ⤷ Sign Up | Modified macrocyclic compounds | BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE) | ⤷ Sign Up |
| Darinaparsin | ⤷ Sign Up | Anti-CS1 antibodies and antibody drug conjugates | AbbVie Biotherapeutics Inc. (Redwood City, CA) | ⤷ Sign Up |
| Darinaparsin | ⤷ Sign Up | ASH1L inhibitors and methods of treatment therewith | The Regents of the University of Michigan (Ann Arbor, MI) | ⤷ Sign Up |
| Darinaparsin | ⤷ Sign Up | AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections | Merck Sharp & Dohme Corp. (Rahway, NJ) Southern Research Institute (Birmingham, AL) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Darinaparsin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Darinaparsin | Australia | AU2015339012 | 2034-10-31 | ⤷ Sign Up |
| Darinaparsin | Brazil | BR112017008945 | 2034-10-31 | ⤷ Sign Up |
| Darinaparsin | Canada | CA2966005 | 2034-10-31 | ⤷ Sign Up |
| Darinaparsin | European Patent Office | EP3212668 | 2034-10-31 | ⤷ Sign Up |
| Darinaparsin | Spain | ES2832711 | 2034-10-31 | ⤷ Sign Up |
| Darinaparsin | Japan | JP2017537893 | 2034-10-31 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
